Resolve Therapeutics (Seattle, WA), a preclinical-stage biotechnology company focused on the development of lupus treatments, closed a $5.8M Series B financing. Participants include New Science Ventures, Easton Capital and WRF Capital.

Collective IP | The World’s Largest Technology Transfer Office Marketplace

Providing Unrivaled Comprehensive and Accurate Access to Humankinds Most Valuable and Transformative Assets

Receive Collective IP Account Access HERE